全文获取类型
收费全文 | 9973篇 |
免费 | 516篇 |
国内免费 | 150篇 |
专业分类
耳鼻咽喉 | 172篇 |
儿科学 | 94篇 |
妇产科学 | 182篇 |
基础医学 | 1374篇 |
口腔科学 | 158篇 |
临床医学 | 708篇 |
内科学 | 2165篇 |
皮肤病学 | 214篇 |
神经病学 | 750篇 |
特种医学 | 713篇 |
外科学 | 1390篇 |
综合类 | 38篇 |
一般理论 | 3篇 |
预防医学 | 277篇 |
眼科学 | 117篇 |
药学 | 1075篇 |
中国医学 | 175篇 |
肿瘤学 | 1034篇 |
出版年
2023年 | 54篇 |
2022年 | 164篇 |
2021年 | 351篇 |
2020年 | 175篇 |
2019年 | 250篇 |
2018年 | 271篇 |
2017年 | 223篇 |
2016年 | 360篇 |
2015年 | 485篇 |
2014年 | 534篇 |
2013年 | 616篇 |
2012年 | 926篇 |
2011年 | 900篇 |
2010年 | 615篇 |
2009年 | 448篇 |
2008年 | 708篇 |
2007年 | 623篇 |
2006年 | 507篇 |
2005年 | 475篇 |
2004年 | 375篇 |
2003年 | 315篇 |
2002年 | 246篇 |
2001年 | 155篇 |
2000年 | 160篇 |
1999年 | 112篇 |
1998年 | 66篇 |
1997年 | 50篇 |
1996年 | 36篇 |
1995年 | 33篇 |
1994年 | 23篇 |
1993年 | 12篇 |
1992年 | 33篇 |
1991年 | 39篇 |
1990年 | 30篇 |
1989年 | 33篇 |
1988年 | 28篇 |
1987年 | 28篇 |
1986年 | 18篇 |
1985年 | 28篇 |
1984年 | 17篇 |
1983年 | 12篇 |
1981年 | 7篇 |
1980年 | 6篇 |
1979年 | 12篇 |
1978年 | 8篇 |
1974年 | 6篇 |
1973年 | 8篇 |
1971年 | 7篇 |
1969年 | 7篇 |
1968年 | 9篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
Richard Kim Elaine Tan Emily Wang Amit Mahipal Dung-Tsa Chen Biwei Cao Fadzai Masawi Cindy Machado James Yu Dae Won Kim 《The oncologist》2020,25(12):e1893-e1899
Lessons Learned
- The combination of trametinib and sorafenib has an acceptable safety profile, albeit at doses lower than approved for monotherapy.
- Maximum tolerated dose is trametinib 1.5 mg daily and sorafenib 200 mg twice daily.
- The limited anticancer activity observed in this unselected patient population does not support further exploration of trametinib plus sorafenib in patients with hepatocellular carcinoma.
4.
Paul Tetteh Asare Nadeeka Bandara Tae-Yong Jeong Sangryeol Ryu Jochen Klumpp Kwang-Pyo Kim 《Archives of virology》2015,160(10):2647-2650
5.
6.
7.
8.
Post-transplantation diabetes is better controlled after conversion from prednisone to deflazacort: a prospective trial in renal transplants 总被引:2,自引:0,他引:2
Yu Seun Kim Myoung Soo Kim Soon Il Kim Seung Kil Lim Ho Yung Lee Dae Suk Han Kiil Park 《Transplant international》1997,10(3):197-201
It is well known that long-term use of steroids plays a decisive role in the development of glucose intolerance and diabetes
mellitus (DM). Deflazacort, an oxazoline derivative of prednisolone, has been introduced as a potential substitute for conventional
steroids in order to ameliorate glucose intolerance. We initiated a randomized study of conversion from prednisone to deflazacort
in kidney transplantation (Tx) recipients presenting with pre-Tx or post-Tx DM to ascertain whether or not the switch to deflazacort
would ameliorate the diabetic state. Forty-two recipients in the conversion group were compared with 40 patients on prednisone
(the control group) in a prospective manner. The dose reduction of insulin or oral blood glucose-lowering agents, the adequacy
of glucose control, and the development of side effects were the criteria for evaluating outcome. In the conversion group,
patients were switched to deflazacort at a dose ratio of 6 mg deflazacort to 5 mg prednisone. During the mean follow-up period
of 13.2 months, neither graft dysfunction nor acute rejection developed in the conversion group. Improvement in blood glucose
control in the conversion group was noted. When the conversion group was stratified into pre- or post-Tx DM, promising effects
were clearly evident in the post-Tx DM patients. More than 50 % dose reduction of blood glucose-lowering agents was possible
in 42.3 % of post-Tx DM patients. In conclusion, it was readily possible to control blood glucose better in post-Tx DM recipients
without seriously affecting the immunosuppressive activity after conversion to deflazacort.
Received: 20 August 1996 Received after revision: 25 November 1996 Accepted: 6 December 1996 相似文献
9.
10.
J. K. Kang Sang Won Lee Min Woo Baik Byung Chul Son Yong Kil Hong Chul Ku Jung Keon Hee Ryu 《Child's nervous system》1998,14(7):297-301
Accurate assessment and replacement of blood loss and fluid–electrolyte deficit during craniosynostosis repair is difficult
owing to patient size and the diversity of surgical technique. Forty-three patients undergoing primary craniosynostosis repair
over a 10-year period were studied retrospectively to determine blood loss and fluid deficit and to assess blood transfusion
practices during both intraoperative and postoperative periods. Blood loss was calculated on the basis of estimated red cell
mass (ERCM) and fluid-electrolyte imbalance was investigated with blood samplings. Blood transfusion was considered appropriate
if the postoperative or posttransfusion ERCM was within 12% of the preoperative value. Estimated fluid requirement (EFR) was
used in 4 ml kg–1 h–1 except for neonates. Intraoperatively, 80% of all patients were appropriately managed with respect to blood transfusion and
EFR. Postoperatively only 20% of the patients receiving transfusions were transfused appropriately. In 23.3% of these patients
(10/43) unexpected respiratory distress developed immediately after their recovery from the anesthesia. With the measurement
of estimated blood volume and allowable blood loss, appropriate transfusion could be achieved for the successful treatment
of the primary craniosynostosis.
Received: 16 February 1998 相似文献